German medicinal cannabis distributor Fette Pharma GmbH has reported the successful completion of a strategic restructuring, almost seven months after an investor consortium led by entrepreneur Jörg Löser acquired the Egelsbach-based company in September 2025.
It marked the end for the former ownership of Fette Pharma under Salis Holding GmbH. A Frankfurt-based holding firm that controlled the business from 2019.Â
The incoming consortium, which also includes Maik Dobiey, who now serves as co-Managing Director alongside Löser, has since completed what the company describes as a significant overhaul of its supply chain, quality assurance processes, and distribution infrastructure.
“Our goal from the outset was not only to stabilise Fette Pharma, but also to position it as an innovation leader in the field of cannabinoid therapy,” said Löser. “Today we can say: Fette Pharma is back, with more effective structures, stronger partners, but with the same high level of pharmaceutical expertise and a clear focus on patient care.”
READ MORE…
Fette Pharma has been in business for over five decades, and brings a wealth of experience to the cannabis market. The company is a major supplier of pharmaceutical cannabis to medical centers and pharmacies in Germany since 2017, the year that medicinal cannabis prescriptions were first allowed.
The partnership was launched in 2022 and marked the introduction of Israeli medicinal cannabis on the German market.
It was based on Cannbit’s research legacy and included ties to the late Professor Raphael Mechoulam’s work. Fette Pharma also gained access to over 40,000 patient therapy data across 37 clinical and non-clinical trials.Â
Re:CANNIS is EU-GMP and GDP certified. Its products include flower extracts and are suitable for a wide range of conditions including chronic and acute pain, fibromyalgia and neurological diseases.
Its restructuring has preserved this pharmaceutical core, while bringing cannabis industry expertise to the forefront under Löser and Dobiey.Â
Fette Pharma has stated that it will expand its portfolio of products and create new partnerships internationally during the current financial year. It also plans to strengthen its position in the German medical market.Â
The company has also repositioned itself more explicitly as a market entry partner for international cultivators and brands seeking access to German pharmacies, offering GDP- and GMP-certified logistics, integrated supply chain support, and direct pharmacy network access without broker intermediaries.